Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 and anti-CTLA-4 therapies, demonstrated clinical efficacy in the treatment of various malignancies including melanoma [7], renal cell carcinoma [8], otorhinolaryngological cancers, and lung cancer as non-small cell lung cancer [9]. The gene discussed is CTLA4; the disease is melanoma.